Viatris Inc. has seen its stock price rise by 4.22%, reaching a 52-week high amid a broader market decline, with the Nasdaq-100 down 0.34% and the S&P 500 down 0.32%.
The company announced the appointment of Lara Ramsburg as Chief People and Corporate Affairs Officer, a move aimed at enhancing company culture and global connectivity through improved communication strategies. Ramsburg, with over 25 years of experience, will oversee critical areas such as global talent and employee experience, which are essential for the company's strategic execution during its transformation phase.
This leadership change is expected to bolster employee engagement and corporate image, supporting Viatris as it enters its next growth phase. The focus on employee well-being and development is seen as vital for achieving the company's strategic objectives.
Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 13.25 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 13.25 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
1 Sell
Hold
Current: 12.970
Low
10.00
Averages
13.25
High
16.00
Current: 12.970
Low
10.00
Averages
13.25
High
16.00
Piper Sandler
Neutral
maintain
$9 -> $12
2026-01-28
New
Reason
Piper Sandler
Price Target
$9 -> $12
AI Analysis
2026-01-28
New
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Viatris to $12 from $9 and keeps a Neutral rating on the shares ahead of quarterly results. The firm cites strength for the brand business across a range of geographies, as well as the likelihood of continued steady contribution in developed markets from new product launches.
Argus
Hold
to
Buy
upgrade
$15
2026-01-16
Reason
Argus
Price Target
$15
2026-01-16
upgrade
Hold
to
Buy
Reason
Argus upgraded Viatris to Buy from Hold with a $15 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VTRS
Unlock Now
Argus
Hold
to
Buy
upgrade
$15
2026-01-16
Reason
Argus
Price Target
$15
2026-01-16
upgrade
Hold
to
Buy
Reason
As previously reported, Argus upgraded Viatris to Buy from Hold with a $15 price target. The firm is positive on the company's strategy and notes that its buybacks and debt reduction should aid in earnings, the analyst tells investors in a research note. Viatris shares also trade at a low multiple and offer an attractive entry point for investors, Argus added.
Truist
Les Sulewski
Buy
maintain
$15 -> $16
2026-01-07
Reason
Truist
Les Sulewski
Price Target
$15 -> $16
2026-01-07
maintain
Buy
Reason
Truist analyst Les Sulewski raised the firm's price target on Viatris to $16 from $15 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
